Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL687735 | 0.87 | — | — | |
| SCHEMBL7596747 | 0.87 | — | — | |
| SCHEMBL1986505 | 0.85 | — | — | |
| SCHEMBL2767649 | 0.85 | — | — | |
| SCHEMBL3258955 | 0.82 | — | — | |
| SCHEMBL988606 | 0.82 | — | — | |
| SCHEMBL1744327 | 0.82 | — | — | |
| SCHEMBL6494250 | 0.75 | — | — | |
| SCHEMBL170248 | 0.74 | SMN1; SMN2 (0.33) | CYP2A13ALDH1A1HPGD | |
| SCHEMBL948434 | 0.72 | ALDH1A1 (0.32) | CYP2A13ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8158624-B2 | Purine PI3K inhibitor compounds and methods of use | GENETECH, INC. (US) | 2012-04-17 | — | — | US | disclosed |
| US-20120000533-A1 | PHOTOELECTRIC CONVERSION DEVICE COMPRISING HYDROXAMIC ACID OR A SALT THEREOF AS ADDITIVE AND PROCESS FOR PRODUCING SAME | BASF SE (DE) | 2012-01-05 | — | — | US | disclosed |
| EP-2030971-B1 | PEST CONTROL AGENT CONTAINING NOVEL PYRIDYL-METHANAMINE DERIVATIVE OR SALT THEREOF | ISHIHARA SANGYO KAISHA (JP) | 2011-10-12 | — | — | EP | disclosed |
| US-20110224194-A1 | Staurosporine Derivatives as Inhibitors of FLT3 Receptor Tyrosine Kinase Activity | NOVARTIS PHARMACEUTICALS CORPORATION | 2011-09-15 | — | — | US | disclosed |
| US-7973032-B2 | Staurosporine derivatives for use in alveolar rhabdomyosarcoma | UNIVERSITY OF ZURICH (DE) | 2011-07-05 | — | — | US | disclosed |
| US-7973031-B2 | Leukemia therapy ;myelodyspastic syndrome | NOVARTIS AG (CH) | 2011-07-05 | — | — | US | disclosed |
| EP-2305265-A1 | Combinations comprising staurosporines | Novartis AG (CH) | 2011-04-06 | — | — | EP | disclosed |
| EP-2279188-A1 | PURINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | Genentech, Inc. (US) | 2011-02-02 | — | — | EP | disclosed |
| US-20100216871-A1 | USE OF COMPOUNDS HAVING CCR ANTAGONISM | TSUCHIMORI NOBORU | 2010-08-26 | — | — | US | disclosed |
| US-20100184820-A1 | COMBINATIONS COMPRISING STAUROSPORINES | NOVARTIS AG (CH) | 2010-07-22 | — | — | US | disclosed |
| US-20100160326-A1 | PEST CONTROL AGENT CONTAINING NOVEL PYRIDYL-METHANAMINE DERIVATIVE OR SALT THEREOF | ISHIHARA SANGYO KAISHA, LTD. (JP) | 2010-06-24 | — | — | US | disclosed |
| US-7557101-B2 | 4,5,6,7-tetrahydro-thieno[3,2-c] pyridine derivatives | HOFFMAN-LA ROCHE INC. (US) | 2009-07-07 | — | — | US | disclosed |
| EP-2030971-A1 | PEST CONTROL AGENT CONTAINING NOVEL PYRIDYL-METHANAMINE DERIVATIVE OR SALT THEREOF | ISHIHARA SANGYO KAISHA, LTD. (JP) | 2009-03-04 | — | — | EP | disclosed |
| US-20080146559-A1 | 4,5,6,7-Tetrahydro-Thieno [2,3-C] Pyridine Derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2008-06-19 | — | — | US | disclosed |
| US-20080146558-A1 | 4,5,6,7-Tetrahydro-Thieno [3,2-C] Pyridine Derivatives | HOFFMANN-LA ROCHE, INC. | 2008-06-19 | — | — | US | disclosed |
| US-6541423-B1 | Controlling vegatation | BASF AKTIENGESELLSCHAFT (DE) | 2003-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160326-A1 | PEST CONTROL AGENT CONTAINING NOVEL PYRIDYL-METHANAMINE DERIVATIVE OR SALT THEREOF | HCN1, HCN3, HCN2 | CYP2A13 1824/4885ALDH1A1 3569/4885HPGD 1331/4885 |
| US-20080146558-A1 | 4,5,6,7-Tetrahydro-Thieno [3,2-C] Pyridine Derivatives | HRH4, HRH3, HRH2 | CYP2A13 517/4885ALDH1A1 362/4885HPGD 622/4885 |
| US-20110224194-A1 | Staurosporine Derivatives as Inhibitors of FLT3 Receptor Tyrosine Kinase Activity | FLT3, MCL1, STK25 | CYP2A13 4601/4885ALDH1A1 4308/4885HPGD 2846/4885 |
| US-20100216871-A1 | USE OF COMPOUNDS HAVING CCR ANTAGONISM | CCR1, CCR3, CCR2 | CYP2A13 2145/4885ALDH1A1 1272/4885HPGD 1882/4885 |
| US-20080146559-A1 | 4,5,6,7-Tetrahydro-Thieno [2,3-C] Pyridine Derivatives | HRH4, HRH3, HRH2 | CYP2A13 521/4885ALDH1A1 364/4885HPGD 609/4885 |
| US-20100184820-A1 | COMBINATIONS COMPRISING STAUROSPORINES | MCL1, FLT3, BCL3 | CYP2A13 4795/4885ALDH1A1 2704/4885HPGD 3769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.